Meeting
2015 ASCO Annual Meeting
Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03.
Authors
Yoichi Naito
National Cancer Center Hospital East, Chiba, Japan
Yoichi Naito , Yasuo Ohashi , Isao Yokota , Toru Watanabe , Hiroji Iwata , Shozo Ohsumi , Shinji Ohno , Yasuo Hozumi , Seiichiro Yamamoto , Masato Takahashi , Tomohiko Aihara , Hirofumi Mukai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Other
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11102)
DOI
10.1200/jco.2015.33.15_suppl.11102
Abstract #
11102
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti
Poster
2023 ASCO Breakthrough
The impact of low muscle mass and strength on chemotherapy toxicity in women with early breast cancer.
First Author: Andree Kurniawan Jr.
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
First Author: Thomas Meyskens